

414 Rec'd PCT/PTO 22 JUN 2000

FORM PTO-1390 (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				Beiersdorf 621-KGB	
				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/582119	
INTERNATIONAL APPLICATION NO. PCT/EP99/00056		INTERNATIONAL FILING DATE 7. Januar 1999 (07.01.99)		PRIORITY DATE CLAIMED 22. Januar 1998 (22.01.98)	
TITLE OF INVENTION SEE APPENDIX					
APPLICANT(S) FOR DO/EO/US SEE APPENDIX					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p style="margin-left: 20px;"><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information:</p>					
<p>APPENDIX</p> <p>Copy of Aktenzeichen 198 02 204.2 (first Page Only)</p> <p>Copy of WO 99/37275</p> <p>English translation of Application (pgs. 1-15 - Specification; pgs. 16-17 claims; last pg. Abstract)</p> <p>Copy of International Search Report</p> <p>Copy of XP-002112591 (German) - Copy of Patent Specification 1 537 112</p> <p>Copy of N°1.437.366 (German) - Copy of Offenlegungsschrift 2734059 (German) DE 27 34 059 A1</p> <p>Copy of DE 3820693 A1 (German) - Copy of US Patent No. 4,169,102</p> <p>Copy of N°44356 (German)</p> <p>Copy of Offenlegungsschrift 25 11 600 (German)</p>					

09/582119

U.S. APPLICATION NO. (if known, see 37 CFR 1.53)		INTERNATIONAL APPLICATION NO. PCT/EP99/00056		ATTORNEY'S DOCKET NUMBER Beiersdorf 261-KGB	
17. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	8 - 20 =	0	X \$18.00	\$	
Independent claims	2 - 3 =	0	X \$78.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) 0			+ \$260.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 0	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 840.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
TOTAL FEES ENCLOSED =				\$ 840.00	
				Amount to be:	\$
				refunded	
				charged	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>14-1263</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>14-1263</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO					
Kurt G. Briscoe, Esq. NORRIS, McLAUGHLIN & MARCUS P.A. 660 White Plains Road Tarrytown, NY 10591-5144 914-332-1700					
				SIGNATURE	
				Kurt G. Briscoe	
				NAME	
				33,141	
				REGISTRATION NUMBER	

Beiersdorf 621-KGB
6713-Dr. Wi-ar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : GERHARD BENNER, STEPHNIE VON DER FECHT; JENS
NIELSEN; SABINE SCHULZ

SERIAL NO. : TBA

FILED : HEREWITH

FOR : COSMETIC OF PHARMACEUTICAL PREPARATIONS WITH
A LESS STICKY FEEL, CONTAINING GLYCERIN ESTERS
OF α -HYDROXY CARBOXYLIC ACIDS AND SATURED
FATTY ACIDS

ART UNIT : TBA

EXAMINER : TBA

June 22, 2000

Hon. Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

SIR:

Prior to examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Claim 2, line 1, delete "use of " and substitute -- Method of using --.

Claims 3-8, line 1 in each, after "Claim 1" insert a comma and cancel the balance of the

09582119-062200

line.

REMARKS


The amendments above eliminate multiple dependencies and place "use" claim 2 in the proper "method" format.

Early and favorable action is earnestly solicited.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By


Kurt G. Briscoe
Reg. No. 33,141

KGB:ja
660 White Plains Road
Tarrytown, New York 10591-5144
(914) 332-1700

CERTIFICATE OF MAILING

I hereby certify that the foregoing Preliminary Amendment is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below:

Date:

By


Kurt G. Briscoe

002290 6728560

Beiersdorf Aktiengesellschaft
Hamburg

5

Description

Cosmetic or pharmaceutical preparations having a reduced feeling of stickiness, comprising glycerol esters of α -hydroxycarboxylic acids and saturated fatty acids

10

The present invention relates to cosmetic or pharmaceutical preparations having a reduced feeling of stickiness, to processes for their preparation, and to the use of active ingredients for reducing the feeling of stickiness of cosmetic preparations.

15

The main aim of skincare in the cosmetic sense is to strengthen or rebuild the skin's natural function as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of endogenous substances (e.g. water, natural fats, electrolytes).

20

If this function becomes impaired, increased resorption of toxic or allergenic substances or infection by microorganisms may result, leading to toxic or allergic skin reactions.

25

Another aim of skincare is to compensate for the loss by the skin of sebum and water caused by daily washing. This is particularly important if the natural regeneration ability is inadequate. Furthermore, skincare products should protect against environmental influences, in particular against sun and wind, and delay skin ageing.

30

Medicinal compositions usually comprise one or more medicaments in an effective concentration. For the sake of simplicity, in order to distinguish clearly between cosmetic and medicinal use and corresponding products, reference is

made to the legal provisions in the Federal Republic of Germany (e.g. Cosmetics Directive, Foods and Drugs Act).

5 Cosmetic or dermatological preparations are frequently in the form of finely disperse multiphase systems in which one or more fatty or oily phases are present alongside one or more aqueous phases. Of these systems, the actual emulsions are, in turn, the most widespread.

10 Preparations for cosmetic or therapeutic skincare, in particular, comprise, as essential constituents, mixtures of oils or oil-soluble substances and water or water-soluble substances. Certain constituents of the aqueous phase, e.g. glycerol, but also of the oily phase, e.g. tocopherylacetate, if present in relatively high concentrations, impair the sensory properties of the preparations. This often
15 manifests itself in an increased feeling of stickiness or feeling of greasiness when the corresponding preparations are used, and these then may, in individual cases, be unmarketable since they are not accepted or perceived negatively by the consumer.

20 Although it is known to reduce this feeling of stickiness or feeling of greasiness by adding certain substances, for example a number of selected powder raw materials, in particular talc, apart from the fact that this is only rarely completely successful, such an addition also changes the viscosity of the product in question and reduces the stability.

25 The object was therefore to remedy all of these disadvantages of the prior art. In particular, the aim was to provide products having reduced stickiness or greasiness. Products in the field of care cosmetics, decorative cosmetics and pharmacological technology were likewise to be freed from the disadvantages of the prior art which have been described.

30 It was also an object of the invention to develop cosmetic bases for cosmetic preparations which are well tolerated by the skin.

35 Another object of the present invention was to provide products having as broad an application diversity as possible. For example, the aim was to provide bases for preparation forms such as cleansing emulsions, face care and bodycare preparations, but also to provide distinctly medicinal-pharmaceutical

administration forms, for example preparations against acne and other skin conditions.

Surprisingly, all of these objects are achieved by cosmetic or pharmaceutical preparations characterized by the following features:

They comprise

- (I) one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid,
- (II) one or more fatty alcohols chosen from the group of branched and unbranched alkyl alcohols having 12 to 40 carbon atoms
- (III) they are O/W emulsions.

The invention further relates to the use of combinations of

- (I) one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid,
 - and
 - (II) one or more fatty alcohols chosen from the group of branched and unbranched alkyl alcohols having 12 to 40 carbon atoms,
- for the preparation of nonsticky O/W emulsions or to the use of such combinations for reducing the stickiness of O/W emulsions.

A particularly advantageous citric ester is glycerol stearate citrate. Such citric esters are obtainable, for example, under the product name "IMWITOR® 370" from Hüls AG.

The total amount of one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid in the finished cosmetic or dermatological preparations is advantageously chosen from the range 0.1-10.0% by weight, preferably 0.5-6.0% by weight, based on the total weight of the preparations.

A preferred fatty alcohol used according to the invention is cetylstearyl alcohol (a mixture of 1-hexadecanol and 1-octadecanol in approximately equal parts).

The total amount of one or more fatty alcohols used according to the invention in the finished cosmetic or dermatological preparations is advantageously chosen

from the range 0.1-10.0% by weight, preferably 0.5-6.0% by weight, based on the total weight of the preparations.

5 According to the invention, it is advantageous to choose weight ratios of glycerol esters of α -hydroxycarboxylic acids and saturated fatty acids on the one hand and fatty alcohols on the other hand of from 7:3 to 3:7, preferably from 2:1 to 1:2, particularly preferably about 1:1.

10 According to the invention, it is possible and advantageous to freely choose the proportion of the oily phase of the preparations according to the invention in the range from 5 to 40% by weight, based on the total weight of the preparations.

The basic constituents of the preparations according to the invention which may be used are:

- 15 - water or aqueous solutions
- oils, such as triglycerides of capric or of caprylic acid, but preferably castor oil;
- fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty acids with alcohols of low carbon number, e.g. with
- 20 isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanolic acids of low carbon number or with fatty acids;
- alcohols, diols or polyols of low carbon number, and ethers thereof, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol
- 25 monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.

In particular, mixtures of the solvents given above are used. In the case of alcoholic solvents, water may be a further constituent.

30

For the purposes of the present invention, the oily phase is advantageously chosen from the group of esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids of chain length from 3 to 30 carbon atoms and saturated and/or unsaturated, branched and/or unbranched alcohols of chain

35 length from 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and/or unsaturated, branched and/or unbranched alcohols of chain length from 3 to 30 carbon atoms. Such ester oils can then advantageously

be chosen from the group consisting of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, 5 oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, and synthetic, semisynthetic and natural mixtures of such esters, e.g. jojoba oil.

In addition, the oily phase can be advantageously chosen from the group of branched and unbranched hydrocarbons and hydrocarbon waxes, silicone oils, 10 dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, namely the triglycerol esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids of chain length from 8 to 24, in particular 12-18 carbon atoms. The fatty acid triglycerides can, for example, be advantageously chosen from the group of synthetic, 15 semisynthetic and natural oils, e.g. olive oil, sunflower oil, soya oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.

For the purposes of the present invention any mixtures of such oil and wax components can also advantageously be used. In some instances, it may also be 20 advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oily phase.

The oily phase is advantageously chosen from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C₁₂₋₁₅-alkyl benzoate, caprylic/capric triglyceride, dicaprylyl 25 ether.

Particularly advantageous mixtures are those comprising C₁₂₋₁₅-alkylbenzoate and 2-ethylhexyl isostearate, those comprising C₁₂₋₁₅-alkyl benzoate and isotridecyl 30 isononanoate, and mixtures of C₁₂₋₁₅-alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.

Of the hydrocarbons, paraffin oil, squalane and squalene are to be used advantageously for the purposes of the present invention.

35 The oily phase can advantageously additionally have a content of cyclic or linear silicone oils, or consist entirely of such oils, although it is preferred to use an

additional content of other oily phase components apart from the silicone oil or the silicone oils.

5 Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention. However, other silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly(methylphenylsiloxane).

10 Particularly advantageous are also mixtures of cyclomethicone and isotridecyl isononanoate, and of cyclomethicone and 2-ethylhexylisostearate.

15 For the purposes of the present invention, emulsions according to the invention, e.g. in the form of a skin protection cream, a skin lotion, a cosmetic milk, for example in the form of a sunscreen cream or a sunscreen milk, are advantageous and comprise, for example, fats, oils, waxes and/or other fatty substances, and water and one or more emulsifiers, as are customarily used for such a type of formulation.

20 The person skilled in the art is of course aware that demanding cosmetic compositions are in most cases inconceivable without the customary auxiliaries and additives. These include, for example, bodying agents, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, light protection agents, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytic substances etc.

25 Corresponding requirements apply mutatis mutandis to the formulation of medicinal preparations.

30 For the purposes of the present invention, medicinal topical compositions usually comprise one or more medicaments in an effective concentration. For the sake of simplicity, in order to distinguish clearly between cosmetic and medicinal use and corresponding products, reference is made to the legal provisions in the Federal Republic of Germany (e.g. Cosmetics Directive, Foods and Drugs Act).

35 In this connection, it is likewise advantageous to add the combinations, used according to the invention, of glycerol esters of α -hydroxycarboxylic acids and saturated fatty acids on the one hand and fatty alcohols on the other hand as

additive to preparations which already comprise other active ingredients for other purposes.

Accordingly, for the purposes of the present invention, cosmetic or topical dermatological compositions can, depending on their composition, be used for example as skin protection cream, cleansing milk, sunscreen lotion, nourishing cream, day cream or night cream etc. In some instances, it is possible and advantageous to use the compositions according to the invention as a base for pharmaceutical formulations.

10

Those cosmetic and dermatological preparations which exist in the form of a sunscreen are also favourable. In addition to the active ingredient used according to the invention, these also preferably comprise at least one UVA filter substance and/or at least one UVB filter substance and/or at least one inorganic pigment.

15

However, it is also advantageous for the purposes of the present invention to provide cosmetic and dermatological preparations whose main purpose is not protection against sunlight, but which nevertheless still comprise anti-UV substances. Thus, for example, UV-A and UV-B filter substances are usually incorporated into day creams.

20

Preparations according to the invention can advantageously comprise substances which absorb UV radiation in the UVB region, the total amount of filter substances being, for example, from 0.1% by weight to 30% by weight, preferably from 0.5 to 10% by weight, in particular from 1 to 6% by weight, based on the total weight of the preparations.

25

The UVB filters can be oil-soluble or water-soluble. Examples of oil-soluble substances which may be mentioned are:

30

- 3-benzylidenecamphor and derivatives thereof, e.g. 3-(4-methylbenzylidene)camphor,
- 4-aminobenzoic acid derivatives, preferably 2-ethylhexyl 4-(dimethylamino)benzoate, amyl 4-(dimethylamino)benzoate;
- esters of cinnamic acid, preferably 2-ethylhexyl 4-methoxycinnamate, isopentyl 4-methoxycinnamate;
- esters of salicylic acid, preferably 2-ethylhexyl salicylate, 4-isopropylbenzyl salicylate, homomenthyl salicylate;

35

- derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
- esters of benzalmalonic acid, preferably di(2-ethylhexyl) 4-methoxybenzalmalonate;
- 2,4,6-trianilino(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5-triazine

Advantageous water-soluble substances are:

- 2-phenylbenzimidazole-5-sulphonic acid and salts thereof, for example sodium, potassium or triethanolammonium salts,
- sulphonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulphonic acid and its salts;
- sulphonic acid derivatives of 3-benzylidenecamphor, such as, for example, 4-(2-oxo-3-bornylidenemethyl)benzenesulphonic acid, 2-methyl-5-(2-oxo-3-bornylidenemethyl)sulphonic acid and its salts.

The list of given UVB filters which can be used according to the invention is of course not intended to be limiting.

- It can also be advantageous to use UVA filters which are usually present in cosmetic and/or dermatological preparations in the preparations according to the invention. Such filter substances are preferably derivatives of dibenzoylmethane, in particular 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane-1,3-dione and 1-phenyl-3-(4'-isopropylphenyl)propane-1,3-dione. Preparations which contain these combinations are also provided by the invention. The same amounts of UVA filter substances which were given for UVB filter substances can be used.

- For the purposes of the present invention, cosmetic and/or dermatological preparations can also comprise inorganic pigments which are usually used in cosmetics for protecting the skin against UV radiation. These are oxides of titanium, zinc, iron, zirconium, silicon, manganese, aluminium, cerium and mixtures thereof, and modifications in which the oxides are the active agents. Particular preference is given to pigments based on titanium dioxide. The quantities given for the above combinations can be used.

- The cosmetic and dermatological preparations according to the invention can comprise cosmetic active ingredients, auxiliaries and/or additives as are usually

used in such preparations, for example antioxidants, preservatives, bactericides, perfumes, antifoams, dyes, pigments which have a colouring effect, thickeners, surfactants, emulsifiers, softeners, moisturizers and/or humectants, fats, oils, waxes or other customary constituents of a cosmetic or dermatological formulation, such
5 as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.

For the purposes of the present invention, it is advantageous to add other antiirritative or antiinflammatory active ingredients to the preparations, in particular
10 batyl alcohol (α -octadecyl glyceryl ether), selachyl alcohol (α -9-octadecenyl glyceryl ether), chimyl alcohol (α -hexadecyl glyceryl ether), bisabolol and/or panthenol.

It is likewise advantageous to add conventional antioxidants to the preparations for the purposes of the present invention. According to the invention, favourable
15 antioxidants used can be any antioxidants which are suitable or customary for cosmetic and/or dermatological applications.

The antioxidants are advantageously selected from the group consisting of amino
20 acids (for example glycine, histidine, tyrosine, tryptophan) and derivatives thereof, imidazoles (e.g. urocanic acid) and derivatives thereof, peptides such as D,L-carnosine, D-carnosine, L-carnosine and derivatives thereof (e.g. anserine), carotenoids, carotenes (e.g. α -carotene, β -carotene, ψ -lycopene) and derivatives thereof, lipoic acid and derivatives thereof (e.g. dihydrolipoic acid), aurothioglucose,
25 propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and the glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ -linoleyl, cholesteryl and glyceryl esters thereof) and salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and
30 salts) and sulfoximine compounds (e.g. buthionine sulfoximines, homocysteine sulfoximine, buthionine sulphones, penta-, hexa-, heptathionine sulfoximine) in very small tolerated doses (e.g. pmol to μ mol/kg), also (metal) chelating agents (e.g. α -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α -hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin,
35 biliverdin, EDTA, EGTA and derivatives thereof, unsaturated fatty acids and derivatives thereof (e.g. γ -linolenic acid, linoleic acid, oleic acid), folic acid and derivatives thereof, furfurylidene sorbitol and derivatives thereof, ubiquinone and

ubiquinol and derivatives thereof, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g. vitamin E acetate), vitamin A and derivatives (vitamin A palmitate), and coniferylbenzoate of benzoin, rutinic acid and derivatives thereof, α -glucosylrutin, ferulic acid, 5 furfurylidene-glucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiac resin acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and derivatives thereof, mannose and derivatives thereof, zinc and derivatives thereof (e.g. ZnO, ZnSO₄), selenium and derivatives thereof (e.g. selenium methionine), stilbenes and derivatives thereof (e.g. stilbene oxide, trans- 10 stilbene oxide) and the derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of said active ingredients which are suitable according to the invention.

The amount of antioxidants (one or more compounds) in the preparations is 15 preferably from 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the preparation.

If vitamin E and/or derivatives thereof are used as the antioxidant(s), it is 20 advantageous to choose their respective concentrations from the range 0.001 - 10% by weight, based on the total weight of the formulation.

For the purposes of the present invention, suitable propellants for cosmetic and/or dermatological preparations which can be sprayed from aerosol containers are the 25 customary known, readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used on their own or in mixtures with one another. The use of compressed air is also advantageous.

The person skilled in the art obviously knows that there are propellant gases which 30 are non-toxic per se which would in principle be suitable for realizing the present invention in the form of aerosol preparations but which, because of their harmful effect on the environment or other accompanying circumstances, should nevertheless be avoided, in particular fluorinated hydrocarbons and chlorofluorocarbons (CFCs).

35 For the purposes of the present invention, if the cosmetic or dermatological preparations are in the form of a lotion which is rinsed out and is used, for example, before or after bleaching, before or after shampooing, between two

shampooing steps, or before or after permanent wave treatment, the preparations are, for example, aqueous or aqueous-alcoholic solutions, which optionally comprise surface-active substances, preferably nonionic or cationic surface-active substances, the concentration of which can be between 0.1 and 10% by weight, preferably between 0.2 and 5% by weight. These cosmetic and/or dermatological preparations can also be aerosols with the auxiliaries usually used for this purpose.

For the purposes of the present invention, a cosmetic preparation in the form of a lotion which is not rinsed out, in particular a lotion for setting the hair, a lotion which is used for blow-drying the hair, a styling and treatment lotion, is generally an aqueous, alcoholic or aqueous-alcoholic solution and comprises at least one cationic, anionic, nonionic or amphoteric polymer, or else mixtures thereof, as well as the active ingredient combinations according to the invention. The amount of polymers used is, for example, between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.

For the purposes of the present invention, cosmetic preparations for the treatment and care of the hair which comprise the active ingredient used according to the invention can be in the form of emulsions which are of the nonionic or anionic type. Nonionic emulsions comprise, as well as water, oils or fatty alcohols, which can also be polyethoxylated or polypropoxylated, for example, or also mixtures of the two organic components. If appropriate, these emulsions comprise cationic surface-active substances.

For the purposes of the present invention, cosmetic preparations for the treatment and care of the hair can be in the form of gels which, in addition to an effective content of active ingredient according to the invention and solvents which are usually used therefor, preferably water, also contain organic thickeners, e.g. gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose or inorganic thickeners, e.g. aluminium silicates, such as, for example, bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate. The thickener is present in the gel, for example, in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.

The examples below serve to illustrate the present invention.

Example 1

	% by weight
Paraffin oil	5.00
Ethanol	3.00
Glycerol	3.00
Glycerol stearate citrate	2.00
Cetylstearyl alcohol	2.00
Dimethicone	1.00
Carbomer	0.10
Wool wax alcohol	0.10
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 2

	% by weight
Paraffin oil	40.00
Ethanol	3.00
Glycerol	3.00
Glycerol stearate citrate	2.00
Cetylstearyl alcohol	2.00
Dimethicone	1.00
Carbomer	0.10
Wool wax alcohol	0.10
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 3

	% by weight
Wool wax alcohol	0.10
Glycerol stearate citrate	2.00
Paraffin oil	9.00
Cetylstearyl alcohol	2.00

Carbomer	0.10
Dimethicone	1.00
Glycerol	3.00
Ethanol	3.00
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 4

	% by weight
Wool wax alcohol	0.10
Glycerol stearate citrate	2.00
Paraffin oil	14.00
Cetylstearyl alcohol	2.00
Carbomer	0.10
Dimethicone	1.00
Glycerol	3.00
Ethanol	3.00
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 5

	% by weight
Wool wax alcohol	0.10
Glycerol stearate citrate	2.00
Paraffin oil	19.00
Cetylstearyl alcohol	2.00
Carbomer	0.10
Dimethicone	1.00
Glycerol	3.00
Ethanol	3.00
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

09158219-062200

Example 6

	% by weight
Wool wax alcohol	0.10
Glyceryl stearate citrate	2.00
Paraffin oil	24.00
Cetylstearyl alcohol	2.00
Carbomer	0.10
Dimethicone	1.00
Glycerol	3.00
Ethanol	3.00
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 7

	% by weight
Ethanol	3.00
Glycerol	3.00
Isohexadecane	2.00
Caprylic/capric triglyceride	2.00
Paraffin oil	2.00
Glyceryl stearate citrate	1.80
Cetylstearyl alcohol	1.80
Dimethicone	1.00
Carbomer	0.10
Wool wax alcohol	0.10
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 8

	% by weight
Glycerol	5.00
Caprylic/capric triglyceride	5.00
Ethanol	3.00
Paraffin oil	3.00

052219-052200

Microcrystalline wax, paraffin oil	3.00
Cyclomethicone	2.00
Dimethicone	2.00
Octyldodecanol	2.00
Glyceryl stearate citrate	1.80
Cetylstearyl alcohol	1.80
Carbomer	0.20
Wool wax alcohol	0.10
Bisabolol	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Example 9

	% by weight
Caprylic/capric triglyceride	3.50
Glycerol	3.00
Glyceryl stearate citrate	2.40
Cetylstearyl alcohol	2.40
Isohexadecane	2.00
Paraffin oil	2.00
Octyl methoxycinnamate	1.30
Aluminium starch octenylsuccinate	1.00
Dimethicone	1.00
Extract from Glycyrrhiza glabra	0.50
NaEDTA	0.50
Butylmethoxydibenzoylmethane	0.40
Carbomer	0.20
Wool wax alcohol	0.10
Tocopheryl acetate	0.10
Dyes, perfume, preservative	q.s.
Water	ad 100.00

Patent Claims

1. Cosmetic or pharmaceutical preparations characterized by the following features:
- 5 They comprise
- (I) one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid, and
 - (II) one or more fatty alcohols chosen from the group of branched and unbranched alkyl alcohols having 12 to 40 carbon atoms
 - 10 (III) they are O/W emulsions.
2. Use of combinations of
- (I) one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid
 - 15 and
 - (II) one or more fatty alcohols chosen from the group of branched and unbranched alkyl alcohols having 12 to 40 carbon atoms,
- for the preparation of nonsticky O/W emulsions or for reducing the stickiness of O/W emulsions.
- 20
3. Preparations according to Claim 1 or use according to Claim 2, characterized in that the partially neutralized ester of monoglycerides and/or diglycerides of saturated fatty acids with citric acid chosen is glycerol stearate citrate.
- 25
4. Preparations according to Claim 1 or use according to Claim 2, characterized in that the fatty alcohol chosen is cetylstearyl alcohol.
5. Preparations according to Claim 1 or use according to Claim 2,
- 30 characterized in that the total amount of one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid in the preparations is chosen from the range 0.1-10.0% by weight, preferably 0.5-6.0% by weight, based on the total weight of the preparations.
- 35
6. Preparations according to Claim 1 or use according to Claim 2, characterized in that the total amount of one or more fatty alcohols in the finished cosmetic or dermatological preparations is chosen from the range 0.1-10.0% by

weight, preferably 0.5-6.0% by weight, based on the total weight of the preparations.

7. Preparations according to Claim 1 or use according to Claim 2,
- 5 characterized in that weight ratios of partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid on the one hand and fatty alcohols on the other hand are chosen from the range from 7:3 to 3:7, preferably from 2:1 to 1:2, particularly preferably about 1:1.
- 10 8. Preparations according to Claim 1 or use according to Claim 2, characterized in that the proportion of the oily phase in the preparations according to the invention is chosen in the range from 5 to 40% by weight, based on the total weight of the preparations.

0958219-06200

Abstract

Cosmetic or pharmaceutical preparations characterized by the following features:

They comprise:

- (I) one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid,
- (II) one or more fatty alcohols chosen from the group of branched and unbranched alkyl alcohols having 12 to 40 carbon atoms,
- (III) and they are O/W emulsions.

0915382419-062200

COMBINATION DECLARATION & POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled „**Cosmetic or pharmaceutical preparations having a reduced feeling of stickiness, comprising glycerol esters of α -hydroxycarboxylic acids and saturated fatty acids**“ the specification of which is attached hereto.

-OR-

was filed on _____ as

Application Serial No. _____ and was amended _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed
<u>198 02 204.2</u> (Number)	<u>Germany</u> (Country)	<u>22/01/1998</u> (Day/Month/Yr. Filed)	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no
_____ (Number)	_____ (Country)	_____ (Day/Month/Yr. Filed)	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>PCT/EP99/00056</u> (Application Serial No.)	<u>07/01/1999</u> (Filing Date)	<u>pending</u> (Status)
(patented, pending, abandoned)		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punished by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named Inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Kurt G. Briscoe, Reg. No. 33,141; William C. Gerstenzang, Reg. No. 27,552; Carmella A. O'Gorman, Reg. No. 33,749; and Stephen G. Ryan, Reg. No. 39,015 all of 660 White Plains Road, Tarrytown, New York 10591-5144; William R. Robinson, Reg. No. 27,224; Mark A. Montana, Reg. No. 44,948 all of 721 Route 202-206, Bridgewater, New Jersey 08807; Lorimer P. Brooks, Reg. No. 15,155; Davy E. Zoneraich, Reg. No. 37,267 all of 805 Third Avenue, 9th Floor, New York, NY 10022, my attorneys with full power of substitution and revocation.

Send Correspondence To:

Norris McLaughlin & Marcus, P.A.
660 White Plains Road
Tarrytown, N. Y. 10591-5144

Direct Telephone Calls To:

(914) 332-1700

Full Name Of Sole or First Inventor Dr. Gerhard Benner	Inventor's Signature <i>G. Benner</i>	Date 13.6.
Residence Eckdahl 61D, D-21614 Buxtehude, Germany DEX	Citizenship German	
Post Office Address Eckdahl 61D, D-21614 Buxtehude, Germany		
Full Name Of Second Inventor Sabine Schulz	Inventor's Signature <i>Sabine Schulz</i>	Date 29.05.00
Residence Siebenschön 12, D-22529 Hamburg, Germany DEX	Citizenship German	
Post Office Address Siebenschön 12, D-22529 Hamburg, Germany		
Full Name Of Third Inventor Stephanie von der Fecht	Inventor's Signature <i>Stephanie von der Fecht</i>	Date 25/05/2000
Residence Blankeneser Chaussee 32B, D-22869 Schenefeld, Germany DEX	Citizenship German	
Post Office Address Blankeneser Chaussee 32B, D-22869 Schenefeld, Germany		
Full Name Of Fourth Inventor Jens Nielsen	Inventor's Signature <i>Jens Nielsen</i>	Date 29/05/2000
Residence Adlerhorst 20D, D-24558 Henstedt-Ulzburg, Germany DEX	Citizenship German	
Post Office Address Adlerhorst 20D, D-24558 Henstedt-Ulzburg, Germany		
Full Name Of Fifth Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		
Full Name Of Sixth Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		
Full Name Of Seventh Inventor	Inventor's Signature	Date
Residence	Citizenship	
Post Office Address		